ARTBIO is a Biotech company based in Cambridge, Massachusetts. It has raised $245M in total funding. Latest round: Series B.
ARTBIO funding overview
ARTBIO is a Biotech company based in Cambridge, Massachusetts. ARTBIO has raised $245M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in July 2024. The round record for ARTBIO runs through 2024; nothing later has been disclosed. Investors on record include F-Prime Capital, Omega Funds, Third Rock Ventures, Sofinnova Investments, B Capital, Qatar Investment Authority and 1 others. 7 distinct backers are named across the disclosed rounds.
ARTBIO at a glance
Total raised
$245M
Latest round
Series B
Latest round date
July 2024
Industry
Biotech
Headquarters
Cambridge, Massachusetts
Notable investors
F-Prime Capital, Omega Funds, Third Rock Ventures, Sofinnova Investments, B Capital, Qatar Investment Authority, Alexandria Venture Investments
Frequently asked about ARTBIO funding
How much has ARTBIO raised?
ARTBIO has raised $245M in total disclosed funding across the rounds on record.
Who has invested in ARTBIO?
F-Prime Capital, Omega Funds, Third Rock Ventures, Sofinnova Investments, B Capital, Qatar Investment Authority are named among the investors backing ARTBIO.
What was the latest ARTBIO funding round?
The most recent disclosed round is a Series B, announced in July 2024.
Where is ARTBIO based?
ARTBIO is based in Cambridge, Massachusetts.
What sector does ARTBIO operate in?
ARTBIO is tracked under Biotech from Cambridge, Massachusetts, with $245M in disclosed funding.
When did ARTBIO last raise?
The last disclosed ARTBIO round closed in July 2024 at Series B.
We update the ARTBIO record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related Biotech companies in Cambridge and their backers are listed below.
